A novel neoadjuvant treatment is being explored for uveal melanoma, a rare form of eye cancer. The treatment involves various combinations of immune checkpoint inhibitors and other therapies, with some outlets reporting on specific drug combinations and designations, such as darovasertib receiving FDA breakthrough therapy designation. The effectiveness and safety of these treatments are being investigated in ongoing trials, including the Morpheus-Melanoma trial, with some showing potential benefits in terms of progression-free survival.